2. Search Result
Search Result
Results for "

RIPK1 kinase

" in MedChemExpress (MCE) Product Catalog:

27

Inhibitors & Agonists

6

Recombinant Proteins

1

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-114371
    Eclitasertib

    DNL-758; SAR-443122

    		 RIP kinase Inflammation/Immunology
    Eclitasertib (DNL-758) is a potent receptor-interacting protein kinase 1 (RIPK1) inhibitor with an IC50 of 0.0375 µΜ .
    Eclitasertib
  • HY-114492
    GSK547

    GSK'547

    		 RIP kinase Cancer
    GSK547 (GSK'547) is a highly selective and potent inhibitor of receptor-interacting serine/threonine protein kinase 1 (RIPK1), inhibits macrophage-mediated adaptive immune tolerance in pancreatic cancer .
    GSK547
  • HY-148297
    Ocadusertib

    LY3871801; R 552

    		 RIP kinase Inflammation/Immunology
    Ocadusertib is a potent Serine/Threonine kinase receptor-interacting protein kinase 1 (RIPK1) inhibitor .
    Ocadusertib
  • HY-138779
    ICCB-19 hydrochloride
    1 Publications Verification

    		 Autophagy RIP kinase Apoptosis Inflammation/Immunology
    ICCB-19 hydrochloride is a TRADD (TNFRSF1A associated via death domain) inhibitor. ICCB-19 hydrochloride binds with N-terminal domain of TRADD (TRADD-N), disrupting its binding to both TRADD-C and TRAF2. ICCB-19 hydrochloride is indirect inhibitor of RIPK1 kinase activity. ICCB-19 hydrochloride effectively induces autophagy and the degradation of long-lived proteins .
    ICCB-19 hydrochloride
  • HY-128348
    PK68

    		RIP kinase Inflammation/Immunology Cancer
    PK68 is a potent orally active and specifical type II inhibitor of receptor-interacting kinase 1 (RIPK1) with an IC50 of ~90 nM, displays inhibition of RIPK1-dependent necroptosis. PK68 powerfully ameliorates TNF-induced systemic inflammatory response syndrome, and can be used for the research of inflammatory disorders and cancer metastasis .
    PK68
  • HY-131064
    RIPK3-IN-1
    1 Publications Verification

    		 RIP kinase Inflammation/Immunology
    RIPK3-IN-1 is a RIPK3 type II DFG-out inhibitor with an IC50 of 9.1 nM. RIPK3-IN-1 inhibits RIPK1 and RIPK2 with IC50s of 5.5 and >10 μM. RIPK3-IN-1 is also a c-Met kinase inhibitor with an IC50 of 1.1 μM .
    RIPK3-IN-1
  • HY-132203
    Necrostatin-34

    		RIP kinase Inflammation/Immunology Cancer
    Necrostatin-34 (Nec-34), a RIPK1 kinase inhibitor, stabilizes RIPK1 kinase in an inactive conformation by occupying a distinct binding pocket in the kinase domain .
    Necrostatin-34
  • HY-148061
    DB1113

    		PROTACs Bcr-Abl CDK Salt-inducible Kinase (SIK) Cyclin G-associated Kinase (GAK) MAP4K MAPKAPK2 (MK2) Ferroptosis ULK LIM Kinase (LIMK) Cancer
    DB1113 (Example 24) is a bifunctional compound targeted protein degradation of kinases. DB1113 degrades ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2, and ULK1. DB1113 can be used for research of disease or disorder mediated by aberrant kinase activity .
    DB1113
  • HY-18901
    RIPK1-IN-4

    		RIP kinase Inflammation/Immunology
    RIPK1-IN-4 (compound 8) is a potent and selective type II kinase inhibitor of receptor interacting protein 1 (RIP1) kinase and binds to a DLG-out inactive form of RIP1 with an IC50s of 16 nM and 10 nM for RIP1 and ADP-Glo kinase .
    RIPK1-IN-4
  • HY-149258
    KWCN-41

    		Necroptosis RIP kinase Mixed Lineage Kinase Inflammation/Immunology
    KWCN-41 is a selective and efficient inhibitor of RIPK1 kinase with an IC50 value of 88 nM. KWCN-41 specifically inhibits cell necrosis but does not inhibit apoptosis. KWCN-41 also has anti-inflammatory effects .
    KWCN-41
  • HY-148382
    RI-962

    		RIP kinase Necroptosis Neurological Disease Inflammation/Immunology
    RI-962 is a potent and selective receptor-interacting protein kinase 1 (RIPK1) inhibitor. RI-962 inhibits RIPK1 with an IC50 value of 35.0 nM. RI-962 can be used for the research of nervous system diseases and inflammatory diseases .
    RI-962
  • HY-161060
    Zharp1-211

    		RIP kinase STAT Inflammation/Immunology Cancer
    Zharp1-211 is a RIPK1 kinase inhibitor with an EC50 of 53 nM and a Kd of 8.7 nM. Zharp1-211 reduces IFN-γ-induced STAT1 activation. Zharp1-211 can be used in the research of graft-versus-host disease and colon cancer .
    Zharp1-211
  • HY-148063
    DB0614

    		PROTACs AAK1 Aurora Kinase CaMK CDK Ferroptosis Salt-inducible Kinase (SIK) LIM Kinase (LIMK) ULK Metabolic Disease
    DB0614 is a PROTAC based on Cereblon ligand, which is a selective and potent targeted protein degrader of NEK9 inhibitor. DB0614 can degrade ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2 and ULK1. DB0614 can be used for research of disease or disorder mediated by aberrant kinase activity .(Blue: Thalidomide-4-OH (HY-103596), Black: linker, Pink: FLT3-IN-17 (HY-148070))
    DB0614
  • HY-178163
    Zharp1-163

    		Ferroptosis Necroptosis RIP kinase Reactive Oxygen Species (ROS) Mixed Lineage Kinase Inflammation/Immunology
    Zharp1-163 is a dual inhibitor of ferroptosis and necroptosis. Zharp1-163 effectively blocks ferroptosis by reducing reactive oxygen species (ROS) levels and inhibits necroptosis by potently and selectively targeting RIPK1 kinase activity (KD = 240 nM; IC50 = 406.1 nM). Zharp1-163 inhibits the cellular activation of RIPK1, RIPK3 and MLKL in response to necroptotic stimulation. Zharp1-163 markedly attenuates TNF-α (HY-P1875)-induced systemic inflammatory syndrome, including the prevention of TNF-α-induced mortality and hypothermia in mice. Zharp1-163 significantly alleviates acute kidney injury associated with both necroptosis and ferroptosis in models induced by Cisplatin (HY-17394) and ischemia-reperfusion. Zharp1-163 can be used for the study of diseases associated with cell death pathways, such as kidney disease .
    Zharp1-163
  • HY-178464
    RIPK1-IN-34

    		RIP kinase Mixed Lineage Kinase Necroptosis Neurological Disease Inflammation/Immunology
    RIPK1-IN-34 is a selective, brain-penetrant RIPK1 inhibitor (IC50 = 126.70 nM) with almost no inhibitory effect on RIPK3 (IC50 ＞ 10, 000 nM). RIPK1-IN-34 offers substantial neuroprotection by inhibiting the phosphorylation of RIPK1, RIPK3, and mixed lineage kinase domain-like pseudokinase (MLKL) within the necroptosis pathway. RIPK1-IN-34 shows the neuroprotective effect in a rat middle cerebral artery occlusion (MCAO) model. RIPK1-IN-34 can be used for the study of anti-acute ischemic stroke (AIS) .
    RIPK1-IN-34
  • HY-162097
    RIPK1-IN-20

    		RIP kinase Necroptosis Cancer
    RIPK1-IN-20 (compound 13c) has a favorable RIPK1 kinase inhibition activity with an IC50 value of 59.8 nM. RIPK1-IN-20 blocks TNFα-induced necroptosis in both human and murine cells (EC50=1.06–4.58 nM) .
    RIPK1-IN-20
  • HY-162880
    RIPK1-IN-24

    		RIP kinase Inflammation/Immunology
    RIPK1-IN-24 is a receptor-interacting protein kinase 1 (RIPK1) inhibitor with an IC50 value of 1.3 μM. RIPK1-IN-24 can be used for research on inflammatory diseases .
    RIPK1-IN-24
  • HY-173574
    RIPK1-IN-31

    		RIP kinase Infection Neurological Disease Inflammation/Immunology
    RIPK1-IN-31 (Compound 36) is a selective allosteric modulator of RIPK1 (receptor-interacting protein kinase 1) with an IC50 value of 16 nM. RIPK1-IN-31 is promising for research of infectious, autoimmune, and neurodegenerative diseases .
    RIPK1-IN-31
  • HY-162237
    RIPK1-IN-22

    		RIP kinase Inflammation/Immunology
    RIPK1-IN-13 (compound 28) is a selective inhibitor for receptor-interacting serine/threonine-protein kinase 1 (RIPK1), the inhibitory activity is measured by ADP-Glo Kinase Assay with a pKi of 7.66. RIPK1-IN-13 inhibits human leukaemia cells U937 with a pIC50 of 7.2 .
    RIPK1-IN-22
  • HY-162928
    RIPK1-IN-26

    		RIP kinase Neurological Disease
    RIPK1-IN-26 (Compound 8a) is a potent receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor with cell anti-necroptosis potency. RIPK1-IN-26 demonstrats good metabolic stability and good binding specificity in mice. RIPK1-IN-26 is promising for research of PET imaging probe development and neurodegenerative disorders .
    RIPK1-IN-26
  • HY-161843
    Necroptosis-IN-4

    		Necroptosis RIP kinase Inflammation/Immunology
    Necroptosis-IN-4, a potent necroptosis inhibitor, is a RIP kinase 1 (RIPK1) inhibitor. Necroptosis-IN-4 has no inhibitory activity against RIPK3 and weak inhibitory activity against VEGFR1/2 and PDGFR-α .
    Necroptosis-IN-4
  • HY-181944
    RIPK1-IN-40

    		RIP kinase Necroptosis Cancer
    RIPK1-IN-40 (Compound 51) is a RIPK1 inhibitor and anti-necroptotic agent (with an EC50 of 0.07 μM against necroptosis). RIPK1-IN-40 binds to the kinase domain of RIPK1, forms hydrogen bond interactions with Met95, and establishes additional polar contacts with Asp156 to stabilize binding, thereby inhibiting necroptosis. RIPK1-IN-40 can be used for the research of colorectal cancer .
    RIPK1-IN-40
  • HY-161911
    Necroptosis-IN-5

    		Necroptosis RIP kinase Neurological Disease Inflammation/Immunology Cancer
    Necroptosis-IN-5 (Compound 26) is an orally active necroptosis inhibitor. Necroptosis-IN-5 also exhibits potent inhibitory activity against receptor-interacting protein kinase 1 (RIPK1). Necroptosis-IN-5 can be used to study necroptosis-related inflammatory diseases, neurodegenerative diseases, and cancers .
    Necroptosis-IN-5
  • HY-157039
    RIPK1-IN-17

    		RIP kinase Necroptosis Mixed Lineage Kinase Inflammation/Immunology
    RIPK1-IN-17 is an orally active, selective RIPK1 inhibitor (Kd = 17 nM) and shows no significant inhibition to RIPK3. RIPK1-IN-17 specifically inhibits necroptosis rather than apoptosis by inhibiting RIPK1, RIPK3, and MLKL phosphorylation. RIPK1-IN-17 protects mice from hypothermia and death. RIPK1-IN-17 can be used for the study of necroptosis-related diseases such as inflammatory response syndrome (SIRS) .
    RIPK1-IN-17
  • HY-170544
    RIPK1-IN-28

    		RIP kinase Inflammation/Immunology
    RIPK1-IN-28 (compound 13) is an orally active RIPK1 inhibitor. RIPK1-IN-28 inhibits human I2.1 and Hepa1‐6 cells with IC50s of 0.4 and 1.2 nM, respectively .
    RIPK1-IN-28
  • HY-144276
    RIPK1-IN-11

    		RIP kinase Inflammation/Immunology
    RIPK1-IN-11 is a potent and orally active RIPK1 inhibitor (Kd=9.2 nM; IC50=67 nM). RIPK1-IN-11 inhibits necroptosis in both human and mouse cells (EC50=17-30 nM). Anti-inflammatory activity .
    RIPK1-IN-11
  • HY-123925
    CSLP43

    		RIP kinase IAP NOD-like Receptor (NLR) Inflammation/Immunology
    CSLP43 is a selective RIPK2 and XIAP inhibitor with an IC50 of 19.9 nM against human RIPK2. CSLP43 binds to the ATP-binding pocket of RIPK2 and disrupts the interaction between RIPK2 and the BIR2 domain of XIAP or cIAP1. CSLP43 inhibits RIPK2 ubiquitination, NOD1-dependent inflammatory signaling pathways, NOD2-dependent inflammatory signaling pathways, as well as NF-κB activation associated with NOD agonists. CSLP43 is selective for the NOD1/NOD2 signaling pathway and does not inhibit the kinase activity of RIPK1 or RIPK3. CSLP43 is applicable to research related to Crohn's disease, Blau syndrome, early-onset sarcoidosis and early-onset inflammatory bowel disease .
    CSLP43

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: